WallStreetZen

NYSE: PFE
Pfizer Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for PFE

Based on 13 analysts offering 12 month price targets for Pfizer Inc.
Min Forecast
$36.00-1.91%
Avg Forecast
$41.92+14.23%
Max Forecast
$53.00+44.41%

Should I buy or sell PFE stock?

Buy
Strong Buy
5 analysts 33.33%
Buy
0 analysts 0%
Hold
10 analysts 66.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Forecast return on equity

Is PFE forecast to generate an efficient return?
Company
30.95%
Industry
74.22%
Market
62.25%
PFE's Return on Equity is forecast to be high in 4 years (30.95%); analysts are confident in the firm's ability to efficiently generate return on equity
Forecast

Forecast return on assets

Is PFE forecast to generate an efficient return on assets?
Company
11.29%
Industry
16.87%
Market
19.66%
PFE is forecast to generate lower Return on Assets (11.29%) than the US Drug Manufacturers - General industry average (16.87%)
Forecast

PFE earnings per share forecast

What is PFE's earnings per share in the next 3 years based on estimates from 2 analysts?
Avg 1 year Forecast
$3.06+95.83%
Avg 2 year Forecast
$3.08+97.33%
Avg 3 year Forecast
$3.19+104.7%
PFE's earnings are forecast to grow at an exceptional rate of 26.97% per year
Forecast

PFE revenue forecast

What is PFE's revenue in the next 3 years based on estimates from 6 analysts?
Avg 1 year Forecast
$55.3B+13.75%
Avg 2 year Forecast
$50.8B+4.52%
Avg 3 year Forecast
$50.3B+3.36%
PFE's revenue is forecast to grow at a rate of 1.11% per year, which is not exceptional
Forecast

PFE earnings growth forecast

How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
26.97%
Industry
24.82%
Market
20.47%
PFE's earnings are forecast to grow faster (26.97% per year) than the US Drug Manufacturers - General industry average (24.82%)
Forecast
PFE's earnings are forecast to grow faster (26.97% per year) than the US market average (20.47%)
Forecast
PFE's earnings are forecast to grow faster (26.97% per year) than the risk-free savings rate (1.1%)
Forecast

PFE revenue growth forecast

How is PFE forecast to perform vs Drug Manufacturers - General companies and vs the US market?
Company
1.11%
Industry
6.43%
Market
14.48%
PFE's revenues are forecast to grow slower (1.11% per year) than the US Drug Manufacturers - General industry average (6.43%)
Forecast
PFE's revenues are forecast to grow slower (1.11% per year) than the US market average (14.48%)
Forecast

Pfizer Stock Forecast FAQ

Is Pfizer Stock a good buy in 2020, according to Wall Street analysts?

The consensus among 15 Wall Street analysts covering (NYSE: PFE) stock is to Buy PFE stock.

Out of 15 analysts, 5 (33.33%) are recommending PFE as a Strong Buy, 0 (0%) are recommending PFE as a Buy, 10 (66.67%) are recommending PFE as a Hold, 0 (0%) are recommending PFE as a Sell, and 0 (0%) are recommending PFE as a Strong Sell.

What is PFE's Price Target?

According to 13 Wall Street analysts that have issued a 1 year PFE price target, the average PFE price target is $41.92, with the highest PFE stock price forecast at $53.00 and the lowest PFE stock price forecast at $36.00.

On average, Wall Street analysts predict that Pfizer's share price could reach $41.92 by Jan 15, 2022. The average Pfizer stock price prediction forecasts a potential upside of 14.23% from the current PFE share price of $36.70.

What is PFE's earnings growth forecast for 2021-2023?

(NYSE: PFE) Pfizer's forecast annual earnings growth rate of 26.97% is forecast to beat the US Drug Manufacturers - General industry's average forecast earnings growth rate of 24.82%, and and it is also forecast to beat the US market's average forecast earnings growth rate of 20.47%.

Pfizer's earnings in 2020 is $8,685,000,000.On average, 2 Wall Street analysts forecast PFE's earnings for 2021 to be $16,976,267,810, with the lowest PFE earnings forecast at $16,670,639,421, and the highest PFE earnings forecast at $17,281,896,200. On average, 6 Wall Street analysts forecast PFE's earnings for 2022 to be $17,105,743,110, with the lowest PFE earnings forecast at $15,170,281,873, and the highest PFE earnings forecast at $18,170,996,969.

In 2023, PFE is forecast to generate $17,744,784,288 in earnings, with the lowest earnings forecast at $15,670,401,056 and the highest earnings forecast at $19,115,666,536.

What is PFE's revenue growth forecast for 2021-2023?

(NYSE: PFE) Pfizer's forecast annual revenue growth rate of 1.11% is not forecast to beat the US Drug Manufacturers - General industry's average forecast revenue growth rate of 6.43%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 14.48%.

Pfizer's revenue in 2020 is $48,648,000,000.On average, 6 Wall Street analysts forecast PFE's revenue for 2021 to be $307,514,205,457,582, with the lowest PFE revenue forecast at $263,073,803,822,994, and the highest PFE revenue forecast at $348,111,791,316,678. On average, 6 Wall Street analysts forecast PFE's revenue for 2022 to be $282,551,462,180,341, with the lowest PFE revenue forecast at $267,146,996,721,525, and the highest PFE revenue forecast at $311,505,678,881,672.

In 2023, PFE is forecast to generate $279,404,389,984,205 in revenue, with the lowest revenue forecast at $267,719,355,341,646 and the highest revenue forecast at $307,054,173,605,880.

What is PFE's Earnings Per Share (EPS) forecast for 2021-2023?

(NYSE: PFE) Pfizer's current Earnings Per Share (EPS) is $1.56. On average, analysts forecast that PFE's EPS will be $3.06 for 2021, with the lowest EPS forecast at $3.00, and the highest EPS forecast at $3.11. On average, analysts forecast that PFE's EPS will be $3.08 for 2022, with the lowest EPS forecast at $2.73, and the highest EPS forecast at $3.27. In 2023, PFE's EPS is forecast to hit $3.19 (min: $2.82, max: $3.44).

What is PFE's forecast return on equity (ROE) for 2021-2024?

(NYSE: PFE) forecast ROE is 30.95%, which is considered strong.

What is PFE's forecast return on assets (ROA) for 2021-2024?

(NYSE: PFE) forecast ROA is 11.29%, which is lower than the forecast US Drug Manufacturers - General industry average of 16.87%.
WallStreetZen
©2021 WallStreetZen
Company
AboutBlogPrivacy PolicyTerms of ServiceContact
Stocks
Stock ScreenerStock ForecastHighest Earnings StocksBest Dividend Paying StocksStatistics
Social
TwitterYouTube
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Heap | Mobile and Web Analytics